Singapore’s Clinical Trials Registry May Attract Wider Patient Pool
This article was originally published in PharmAsia News
The launch of a clinical trials registry in Singapore is another step in the wealthy city-state’s efforts to serve as a treatment hub in Asia for cutting-edge therapies.
You may also be interested in...
The National Institutes of Health is still drafting regulations, but Rep. Markey’s TEST Act, which would impose more extensive reporting requirements, has won praise from stakeholders for some of its definitional details. In an election season, its prospects for passing are slim, but aspects of the legislation could serve as a model for pending regulations.
SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.